Who are Benaglutide Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Liraglutide+standard-of-care treatment, Semaglutide Injectable Product, Lixisenatide (AVE0010), Victoza (liraglutide), Semaglutide Pen Injector [Ozempic], semaglutide combined with metformin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/benaglutide-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Benaglutide Injection — Competitive Intelligence Brief

Benaglutide Injection (Benaglutide Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Diabetes.

marketed GLP-1 receptor agonist GLP-1R Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Benaglutide Injection (Benaglutide Injection) — The Affiliated Hospital of Qingdao University. Benaglutide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Benaglutide Injection TARGET	Benaglutide Injection	The Affiliated Hospital of Qingdao University	marketed	GLP-1 receptor agonist	GLP-1R
Liraglutide+standard-of-care treatment	Liraglutide+standard-of-care treatment	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	GLP-1 receptor agonist	GLP-1R
Semaglutide Injectable Product	Semaglutide Injectable Product	Neurogastrx, Inc.	marketed	GLP-1 receptor agonist	GLP-1R
Lixisenatide (AVE0010)	Lixisenatide (AVE0010)	Sanofi	marketed	GLP-1 receptor agonist	GLP-1R
Victoza (liraglutide)	Victoza (liraglutide)	Zealand University Hospital	marketed	GLP-1 receptor agonist	GLP-1R
Semaglutide Pen Injector [Ozempic]	Semaglutide Pen Injector [Ozempic]	University of Nottingham	marketed	GLP-1 receptor agonist	GLP-1R
semaglutide combined with metformin	semaglutide combined with metformin	The First Affiliated Hospital of Xiamen University	marketed	GLP-1 receptor agonist combined with biguanide	GLP-1R; AMPK pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Benaglutide Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/benaglutide-injection. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab